...
首页> 外文期刊>Journal of cardiac failure >Pro-A-type natriuretic peptide, proadrenomedullin, and n-terminal pro-b-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure
【24h】

Pro-A-type natriuretic peptide, proadrenomedullin, and n-terminal pro-b-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure

机译:Pro-A型利尿钠肽,肾上腺髓质素和n端pro-b型利尿钠肽在初级医疗保健中的多标记策略中用于心力衰竭患者的风险评估

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Objective: Use of new biomarkers in the handling of heart failure patients has been advocated in the literature, but most often in hospital-based populations. Therefore, we wanted to evaluate whether plasma measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP), midregional pro-A-type natriuretic peptide (MR-proANP), and midregional proadrenomedullin (MR-proADM), individually or combined, gives prognostic information regarding cardiovascular and all-cause mortality that could motivate use in elderly patients presenting with symptoms suggestive of heart failure in primary health care. Methods and Results: The study included 470 elderly patients (mean age 73 years) with symptoms of heart failure in primary health care. All participants underwent clinical examination, 2-dimenstional echocardiography, and plasma measurement of the 3 propeptides and were followed for 13 years. All mortality was registered during the follow-up period. The 4th quartiles of the biomarkers were applied as cutoff values. NT-proBNP exhibited the strongest prognostic information with >4-fold increased risk for cardiovascular mortality within 5 years. For all-cause mortality MR-proADM exhibited almost 2-fold and NT-proBNP 3-fold increased risk within 5 years. In the 5-13-year perspective, NT-proBNP and MR-proANP showed significant and independent cardiovascular prognostic information. NT-proBNP and MR-proADM showed significant prognostic information regarding all-cause mortality during the same time. In those with ejection fraction (EF) <40%, MR-proADM exhibited almost 5-fold increased risk of cardiovascular mortality with 5 years, whereas in those with EF >50% NT-proBNP exhibited >3-fold increased risk if analyzed as the only biomarker in the model. If instead the biomarkers were all below the cutoff value, the patients had a highly reduced mortality risk, which also could influence the handling of patients. Conclusions: The 3 biomarkers could be integrated in a multimarker strategy for use in primary health care. ? 2013 Elsevier Inc. All rights reserved.
机译:目的:在文献中已提倡使用新的生物标志物治疗心力衰竭患者,但多数情况是在医院人群中。因此,我们想评估是否分别单独测量血浆N端前B型利尿钠肽(NT-proBNP),中区前A型利尿钠肽(MR-proANP)和中区肾上腺髓质素(MR-proADM)的含量或结合使用,可以提供有关心血管疾病和全因死亡率的预后信息,这些信息可能会促使在出现初级保健中表现出心力衰竭症状的老年患者中使用。方法与结果:该研究纳入了470名老年患者(平均年龄73岁),他们在初级卫生保健中出现心力衰竭症状。所有参与者均接受了临床检查,二维超声心动图和3种前肽的血浆测量,并随访了13年。在随访期间记录所有死亡率。将生物标记的第四个四分位数用作临界值。 NT-proBNP表现出最强的预后信息,在5年内使心血管死亡的风险增加了4倍以上。对于全因死亡率,在5年内MR-proADM的风险增加了近2倍,而NT-proBNP的风险增加了3倍。从5-13年的角度来看,NT-proBNP和MR-proANP显示出重要且独立的心血管预后信息。 NT-proBNP和MR-proADM在同一时间显示了有关全因死亡率的重要预后信息。在射血分数(EF)<40%的患者中,MR-proADM在5年内的心血管死亡风险增加了近5倍,而在EF> 50%的患者中,NT-proBNP的风险增加了3倍以上。模型中唯一的生物标记。相反,如果生物标志物均低于临界值,则患者的死亡风险大大降低,这也可能影响患者的处理。结论:这三种生物标志物可以整合到用于初级卫生保健的多标志物策略中。 ? 2013 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号